Ovid Therapeutics Inc
OVID0.489USD
-0.011-2.18%
交易中 （美東）報價延遲15分鐘
34.78M總市值
虧損本益比TTM
關於 Ovid Therapeutics Inc 公司
Ovid Therapeutics Inc. 是一家生物製藥公司。該公司致力於改善某些癲癇和腦部疾病患者的生活，這些疾病伴有癲癇症狀。該公司致力於推進一系列新型靶向小分子候選藥物，這些藥物可調節引起癲癇和其他神經症狀的神經元興奮過度的內在和外在因素。該公司開發了 OV888 (GV101)，一種強效且高度選擇性的 ROCK2 抑制劑，可用於治療與腦海綿狀血管瘤和其他腦部疾病相關的病變；OV329，一種 GABA-氨基轉移酶抑制劑，可用於治療難治性癲癇；OV350，一種 KCC2 轉運蛋白的直接激活劑，可用於治療癲癇和其他精神疾病。該公司還對 Soticlestat 的開發和商業化感興趣，Soticlestat 是一種用於治療 Dravet 和 Lennox-Gastaut 綜合徵的膽固醇 24-羥化酶抑制劑。
公司簡介
公司代碼OVID
公司名稱Ovid Therapeutics Inc
上市日期May 05, 2017
CEODr. Jeremy Max Levin, Ph.D.
員工數量23
證券類型Ordinary Share
年結日May 05
公司地址441 Ninth Avenue, 14Th Floor
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10001
電話12127764381
網址https://ovidrx.com/
公司代碼OVID
上市日期May 05, 2017
CEODr. Jeremy Max Levin, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
Ms. Margaret (Meg) Alexander
Ms. Margaret (Meg) Alexander
President, Chief Operating Officer
President, Chief Operating Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月23日 週三
更新時間: 7月23日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Takeda Pharmaceutical Co Ltd
10.59%
Levin (Jeremy M)
5.14%
BlackRock Institutional Trust Company, N.A.
5.04%
The Vanguard Group, Inc.
4.37%
Madison Avenue Partners LP
3.47%
Other
71.40%
持股股東
持股股東
佔比
Takeda Pharmaceutical Co Ltd
10.59%
Levin (Jeremy M)
5.14%
BlackRock Institutional Trust Company, N.A.
5.04%
The Vanguard Group, Inc.
4.37%
Madison Avenue Partners LP
3.47%
Other
71.40%
股東類型
持股股東
佔比
Investment Advisor
16.66%
Hedge Fund
13.33%
Investment Advisor/Hedge Fund
10.93%
Corporation
10.59%
Individual Investor
5.72%
Research Firm
1.65%
Bank and Trust
0.20%
Venture Capital
0.13%
Pension Fund
0.03%
Other
40.74%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
175
46.86M
65.90%
-15.45M
2025Q1
183
51.39M
72.29%
-10.07M
2024Q4
181
52.28M
73.63%
-8.46M
2024Q3
175
51.32M
72.31%
-10.19M
2024Q2
172
51.56M
72.67%
-6.81M
2024Q1
174
55.84M
78.97%
-6.53M
2023Q4
174
57.32M
81.09%
-4.46M
2023Q3
183
57.79M
81.95%
-5.02M
2023Q2
192
56.05M
79.62%
-3.53M
2023Q1
194
53.91M
76.62%
-6.14M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Takeda Pharmaceutical Co Ltd
7.53M
10.59%
--
--
Mar 31, 2025
Levin (Jeremy M)
3.65M
5.14%
-20.00
-0.00%
Apr 24, 2025
BlackRock Institutional Trust Company, N.A.
3.58M
5.04%
-59.44K
-1.63%
Mar 31, 2025
The Vanguard Group, Inc.
3.11M
4.37%
-39.30K
-1.25%
Mar 31, 2025
Madison Avenue Partners LP
2.47M
3.47%
-386.73K
-13.56%
Mar 31, 2025
Sio Capital Management, LLC
2.23M
3.14%
+1.23M
+123.20%
Mar 31, 2025
Acadian Asset Management LLC
2.09M
2.94%
+237.44K
+12.83%
Mar 31, 2025
Kennedy Capital Management LLC
1.73M
2.44%
+187.48K
+12.13%
Mar 31, 2025
Driehaus Capital Management, LLC
1.40M
1.97%
--
--
Mar 31, 2025
State Street Global Advisors (US)
1.37M
1.93%
-22.41K
-1.61%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
0%
ProShares Hedge Replication ETF
0%
Avantis Responsible US Equity ETF
0%
查看更多
iShares Russell 2000 Growth ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
Fidelity Enhanced Small Cap ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Avantis Responsible US Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
